For the quarter ended November 2024, Walgreens Boots Alliance (WBA) reported revenue of $39.46 billion, up 7.5% over the same period last year. EPS came in at $0.51, compared to $0.66 in the year-ago quarter.
The reported revenue represents a surprise of +6.41% over the Zacks Consensus Estimate of $37.08 billion. With the consensus EPS estimate being $0.37, the EPS surprise was +37.84%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- U.S. Retail Pharmacy: $30.87 billion compared to the $29.18 billion average estimate based on six analysts. The reported number represents a change of +6.6% year over year.
- Revenues- U.S. Healthcare: $2.17 billion compared to the $2.04 billion average estimate based on five analysts. The reported number represents a change of +12.5% year over year.
- Revenues- International: $6.43 billion versus $5.91 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.
- Adjusted operating income (loss)- U.S. Retail Pharmacy: $441 million versus the four-analyst average estimate of $291.48 million.
- Adjusted operating income (loss)- International: $168 million versus $169.54 million estimated by four analysts on average.
- Adjusted operating income (loss)- U.S. Healthcare: $25 million versus $6.45 million estimated by four analysts on average.
- Adjusted operating income (loss)- Corporate and Other: -$41 million versus -$50 million estimated by three analysts on average.
Shares of Walgreens have returned -5.2% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWalgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
